At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

Two studies presented at ASCO's annual meeting used ctDNA testing to determine which patient might benefit from anti-EGFR retreatment.

Nearly 70% of CRC samples have heterogeneous genetic alterations in genes involved in EGFR signaling, which negatively affect response to the mAbs cetuximab and panitumumab. Furthermore, molecular ...

With a vast global footprint, Amgen’s diverse portfolio has positioned it well in the evolving biotech industry. Growth products like Prolia, Xgeva, Evenity, Vectibix, Nplate and Kyprolis and ...

Amgen AMGN and Bristol Myers Squibb BMY are among the largest global biotechnology companies with broad and diverse ...

Briefly, panitumumab was captured in microplate wells precoated with mouse anti-panitumumab antibody (Amgen Inc., Thousand Oaks, CA, USA). Horseradish peroxidase-labeled rabbit polyclonal anti ...

We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more than $400 million now, and more. From STAT’s Andrew Joseph: Lars Fruergaard ...

Regeneron Pharmaceuticals secured a victory in an antitrust case that accused Amgen Inc. of anticompetitive bundling practices, as a jury awarded the company nearly $407 million in damages Thursday. A ...

A Delaware federal trial jury found Thousand Oaks, California-based drug company Amgen Inc. liable Thursday for federal and state antitrust violations amounting to more than $400 million in damages.

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws ...